ArticleBMC urology2025
Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of metastatic castration-resistant prostate cancer (mCRPC) following progression on androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) in the castration-sensitive (CS) setting remains unclear. Limited data exist comparing the efficacy of ARPI versus docetaxel as first-line treatment in this context.
methodsWe conducted a retrospective multicentre study across three tertiary cancer centres in Saudi Arabia, including 60 patients with pathologically confirmed mCRPC who progressed after doublet therapy (ADT + ARPI) in the CS setting between January 2018 and September 2022. Patients received either ARPI (abiraterone acetate or enzalutamide) or docetaxel as first-line therapy for mCRPC. Primary endpoints were prostate-specific antigen (PSA) response rate and biochemical progression-free survival (PFS). Secondary endpoints included overall survival (OS) and treatment patterns. PSA response was defined as ≥ 30% decline at 12 weeks from baseline. Survival analyses were performed using Kaplan-Meier and log-rank tests.
resultsAmong 60 eligible patients (median age 65 years), 28 received ARPI and 32 received docetaxel. PSA response rates were 39.3% for ARPI and 37.5% for docetaxel. Median PFS was 2.9 months (95% CI 0.37-5.5) for ARPI and 4.5 months (95% CI 2.6-6.3) for docetaxel (p = 0.137). Median OS was 13 months (95% CI 4.0-23.9) for ARPI and 16 months (95% CI 6.1-25.9) for docetaxel (p = 0.236). In patients with visceral metastases, docetaxel conferred significantly longer OS compared to ARPI (14.4 vs. 5.9 months, p = 0.025). Multivariate analysis identified nadir PSA in the CS setting as a predictor of PFS and first-line therapy in the CR setting, visceral metastasis and duration of therapy in CS setting as predictors of OS.
conclusionsIn patients progressing to mCRPC after doublet therapy in the CS setting, docetaxel demonstrated a trend toward longer PFS and OS compared to ARPI, with a significant survival advantage in those with visceral metastases. These findings highlight the need for prospective randomized trials and biomarker-driven treatment strategies to optimize therapy sequencing in this evolving treatment landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.